Journal of Applied Physiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


J Appl Physiol 106: 1311-1324, 2009. First published January 8, 2009; doi:10.1152/japplphysiol.90985.2008
8750-7587/09 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
106/4/1311    most recent
90985.2008v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Burdi, R.
Right arrow Articles by De Luca, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Burdi, R.
Right arrow Articles by De Luca, A.

Multiple pathological events in exercised dystrophic mdx mice are targeted by pentoxifylline: outcome of a large array of in vivo and ex vivo tests

Rosa Burdi,1,* Jean-François Rolland,1,* Bodvael Fraysse,1 Karina Litvinova,1 Anna Cozzoli,1 Viviana Giannuzzi,1 Antonella Liantonio,1 Giulia Maria Camerino,1 Valeriana Sblendorio,1,2 Roberta Francesca Capogrosso,1 Beniamino Palmieri,2 Francesca Andreetta,3 Paolo Confalonieri,3 Leonarda De Benedictis,4 Monica Montagnani,4 and Annamaria De Luca1

1Unit of Pharmacology, Department of Pharmaco-biology, Faculty of Pharmacy, University of Bari, Bari; 2Department of General Surgery and Surgical Specialties, University of Modena, Modena; 3Muscular Pathology Unit, National Neurological Institute Carlo Besta, Milan; and 4Departments of Pharmacology and Human Physiology, Medical School, University of Bari, Bari, Italy

Submitted 31 July 2008 ; accepted in final form 4 January 2009

The phosphodiesterases inhibitor pentoxifylline gained attention for Duchenne muscular dystrophy therapy for its claimed anti-inflammatory, antioxidant, and antifibrotic action. A recent finding also showed that pentoxifylline counteracts the abnormal overactivity of a voltage-independent calcium channel in myofibers of dystrophic mdx mice. The possible link between workload, altered calcium homeostasis, and oxidative stress pushed toward a more detailed investigation. Thus a 4- to 8-wk treatment with pentoxifylline (50 mg·kg–1·day–1 ip) was performed in mdx mice, undergoing or not a chronic exercise on treadmill. In vivo, the treatment partially increased forelimb strength and enhanced resistance to treadmill running in exercised animals. Ex vivo, pentoxifylline restored the mechanical threshold, an electrophysiological index of calcium homeostasis, and reduced resting cytosolic calcium in extensor digitorum longus muscle fibers. Mn quenching and patch-clamp technique confirmed that this effect was paralleled by a drug-induced reduction of membrane permeability to calcium. The treatment also significantly enhanced isometric tetanic tension in mdx diaphragm. The plasma levels of creatine kinase and reactive oxygen species were both significantly reduced in treated-exercised animals. Dihydroethidium staining, used as an indicator of reactive oxygen species production, showed that pentoxifylline significantly reduced the exercise-induced increase in fluorescence in the mdx tibialis anterior muscle. A significant decrease in connective tissue area and profibrotic cytokine transforming growth factor-β1 was solely found in tibialis anterior muscle. In both diaphragm and gastrocnemius muscle, a significant increase in neural cell adhesion molecule-positive area was instead observed. This data supports the interest toward pentoxifylline and allows insight in the level of cross talk between pathogenetic events in workloaded dystrophic muscle.

muscular dystrophy; preclinical test; calcium homeostasis; oxidative stress; exercise; phosphodiesterase inhibitors



Address for reprint requests and other correspondence: A. De Luca, Sezione di Farmacologia, Dipartimento Farmacobiologico, Via Orabona 4, Campus, 70125 Bari, Italy (e-mail: adeluca{at}farmbiol.uniba.it)




This article has been cited by other articles:


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
M. A. Potenza, S. Gagliardi, L. De Benedictis, A. Zigrino, E. Tiravanti, G. Colantuono, A. Federici, L. Lorusso, V. Benagiano, M. J. Quon, et al.
Treatment of spontaneously hypertensive rats with rosiglitazone ameliorates cardiovascular pathophysiology via antioxidant mechanisms in the vasculature
Am J Physiol Endocrinol Metab, September 1, 2009; 297(3): E685 - E694.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2009 by the American Physiological Society.